- Home
- LADR vs VRDN Comparison
LADR vs VRDN Comparison
Compare LADR & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LADR
- VRDN
- Stock Information
- Founded
- LADR 2008
- VRDN 2006
- Country
- LADR United States
- VRDN United States
- Employees
- LADR N/A
- VRDN N/A
- Industry
- LADR Real Estate Investment Trusts
- VRDN Medical Specialities
- Sector
- LADR Real Estate
- VRDN Health Care
- Exchange
- LADR Nasdaq
- VRDN Nasdaq
- Market Cap
- LADR 1.5B
- VRDN 1.5B
- IPO Year
- LADR 2014
- VRDN N/A
- Fundamental
- Price
- LADR $11.39
- VRDN $19.62
- Analyst Decision
- LADR Buy
- VRDN Strong Buy
- Analyst Count
- LADR 2
- VRDN 11
- Target Price
- LADR $12.75
- VRDN $38.80
- AVG Volume (30 Days)
- LADR 584.3K
- VRDN 772.7K
- Earning Date
- LADR 10-23-2025
- VRDN 11-11-2025
- Dividend Yield
- LADR 8.11%
- VRDN N/A
- EPS Growth
- LADR N/A
- VRDN N/A
- EPS
- LADR 0.70
- VRDN N/A
- Revenue
- LADR $243,794,000.00
- VRDN $305,000.00
- Revenue This Year
- LADR N/A
- VRDN N/A
- Revenue Next Year
- LADR $14.29
- VRDN $34,076.08
- P/E Ratio
- LADR $16.22
- VRDN N/A
- Revenue Growth
- LADR N/A
- VRDN 5.90
- 52 Week Low
- LADR $9.68
- VRDN $9.90
- 52 Week High
- LADR $12.22
- VRDN $27.20
- Technical
- Relative Strength Index (RSI)
- LADR 46.79
- VRDN 57.62
- Support Level
- LADR $11.50
- VRDN $17.91
- Resistance Level
- LADR $11.53
- VRDN $20.51
- Average True Range (ATR)
- LADR 0.16
- VRDN 0.95
- MACD
- LADR -0.06
- VRDN -0.09
- Stochastic Oscillator
- LADR 17.69
- VRDN 65.77
About LADR Ladder Capital Corp
Ladder Capital Corp is an internally-managed real estate investment trust that is in commercial real estate finance. The company originates and invests in a diverse portfolio of commercial real estate and real estate-related assets, focusing on senior secured assets. The company's investment activities include: (i) Primary business of originating senior first mortgage fixed and floating rate loans collateralized by commercial real estate with flexible loan structures; (ii) owning and operating commercial real estate, including net leased commercial properties; and (iii) investing in investment-grade securities secured by first mortgage loans on commercial real estate. The company has three reportable segments include loans: which derives maximum profit; securities; and real estate.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).